Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist-Reference-Cited by-同舟云学术

Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist

Published:2022-09 Issue:9 Volume:28 Page:958-968
ISSN:2376-0540
Container-title:Journal of Managed Care & Specialty Pharmacy
language:en
Short-container-title:JMCP

Author:

Edelman Steven¹,Cassarino Doreen²,Kayne David³,Dex Terry⁴,Li Xuan⁴,Pasquel Francisco J⁵

Affiliation:

1. Division of Endocrinology and Metabolism, Department of Medicine, School of Medicine, University of California, San Diego, and Veterans Affairs Medical Center, and Taking Control of Your Diabetes, Solana Beach, CA.

2. Millennium Physician Group, Naples, FL.

3. Cedars Sinai Medical Group, Encino, CA.

4. Sanofi, Bridgewater, NJ.

5. Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, School of Medicine, Emory University, Atlanta, GA.

Publisher

Academy of Managed Care Pharmacy

Subject

Health Policy,Pharmaceutical Science,Pharmacy

Reference23 articles.

1. Economic Costs of Diabetes in the U.S. in 2017

2. Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes

3. Beta-cell failure in type 2 diabetes: mechanisms, markers, and clinical implications